Displaying drugs 501 - 525 of 1415 in total
RRx-001
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
Investigational
Matched Name: … RRx-001 …
Matched Description: … RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma …
Matched Description: … RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma …
SIG-001
SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres.
Investigational
Matched Name: … SIG-001 …
Matched Description: … SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with …
Matched Description: … SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with …
RST-001
RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channel rhodopsin-2 protein.
Investigational
Matched Name: … RST-001 …
Matched Description: … RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene …
Matched Description: … RST-001 is a non-replicating recombinant adeno-associated virus vector containing a fragment of the gene …
AVB-001
AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Investigational
Matched Name: … AVB-001 …
Matched Description: … AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native …
Matched Description: … AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native …
ISP-001
ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and delivery of alpha-L-iduronidase.
Investigational
Matched Name: … ISP-001 …
Matched Description: … ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and …
Matched Description: … ISP-001 consists of sleeping beauty transposon-engineered autologous plasmablasts for expression and …
TASO-001
TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide.
Investigational
Matched Name: … TASO-001 …
Matched Description: … TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide. …
Matched Description: … TASO-001 is a transforming growth factor (TGF)-beta 2 specific antisense oligodeoxynucleotide. …
EXOB-001
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
Matched Name: … EXOB-001 …
Matched Description: … EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal …
Matched Description: … EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal …
AT-001
AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain Health in Aging).
Investigational
Matched Name: … AT-001 …
Matched Description: … AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain …
Matched Description: … AT-001 is under investigation in clinical trial NCT03062384 (AT-001 for Long-term Preservation of Brain …
SVV-001
SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features. SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that...
Investigational
Matched Name: … SVV-001 …
Matched Description: … SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional ... SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable …
Matched Description: … SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. ... SVV-001 has also demonstrated cancer-killing specificity 10,000 times higher than that of traditional ... SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable …
CYP-001
CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from the mesoderm. When activated with fibroblast growth factor-2 (FGF-2), MCAs create colonies with specific phenotypes. These cells are then able to differentiate into bone, cartilage, and adipose tissue.
The MCA-derived MSCs can be obtained from induced pluripotent...
Investigational
Matched Name: … CYP-001 …
Matched Description: … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
Matched Description: … CYP-001 is a mesenchymoangioblast (MCA)-derived mesenchymal stem cell (MSC) therapy that originates from …
STG-001
STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt Disease).
Investigational
Matched Name: … STG-001 …
Matched Description: … STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt …
Matched Description: … STG-001 is under investigation in clinical trial NCT04489511 (Study of STG-001 in Subjects With Stargardt …
TRK-001
TRK-001 is an autologous regulatory T-cell therapy. It is being investigated for the prevention of graft rejection following solid organ transplantation.
Investigational
Matched Name: … TRK-001 …
Matched Description: … TRK-001 is an autologous regulatory T-cell therapy. …
Matched Description: … TRK-001 is an autologous regulatory T-cell therapy. …
BVX-001
BVX001 is a a novel, first-in-class CD33/CD7-directed antibody-drug conjugate.
Investigational
Matched Name: … BVX-001 …
CYNK-001
CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.
Investigational
Matched Name: … CYNK-001 …
Matched Description: … CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental …
Matched Description: … CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental …
ANEB-001
ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test).
Investigational
Matched Name: … ANEB-001 …
Matched Description: … , and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test). ... ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics …
Matched Description: … , and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge Test). ... ANEB-001 is under investigation in clinical trial NCT05282797 (Safety, Tolerability, Pharmacokinetics …
NB-001
NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.
Investigational
Matched Name: … NB-001 …
Matched Description: … NB-001 has been investigated for the treatment of Recurrent Herpes Labialis. …
Matched Description: … NB-001 has been investigated for the treatment of Recurrent Herpes Labialis. …
BS-001
BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).
Investigational
Matched Name: … BS-001 …
Matched Description: … BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell …
Matched Description: … BS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell …
PMI-001
PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc. It is an extract of the roots of an undisclosed perennial shrub which interferes with the production of IL-2 and COX-2 proteins, for the potential treatment of autoimmune diseases, such as rheumatoid arthritis, lupus erythematosus and psoriasis.
Investigational
Matched Name: … PMI-001 …
Matched Description: … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics …
Matched Description: … PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics …
Displaying drugs 501 - 525 of 1415 in total